Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry
NCT ID: NCT03479580
Last Updated: 2022-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1600 participants
OBSERVATIONAL
2018-02-08
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
NCT04577248
Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery
NCT02925819
European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study
NCT06235385
CoreValve Advance International Post Market Study
NCT01074658
Armenian National Registry of Myocardial Infarction
NCT06048003
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Also, new imaging techniques have been developed to assess coronary microvascular disease, but the prognostic value of these findings is not known.
In this study, the investigators evaluate the incidence and the prognosis of bystander coronary artery disease and microvascular disease in patients with ischemic, hypertrophic, dilated and restrictive cardiomyopathies in 5 French centers.
Coronary angiography, cardiac magnetic resonance (CMR), tomographic coronary artery angiography, single-photon emission computed tomography (SPECT), rest and stress trans-thoracic echocardiography (TTE) results will be recorded.
Macrovascular coronary artery disease is defined by :
* a stenosis \> 50 % in coronary angiography confirmed with myocardial ischemia (SPECT, stress echocardiography),
* a stenosis \> 70 % (50% if it is the left main coronary artery)
* or a stenosis 30-70 % with a fractional flow reserve (FFR) \< 0.8 Microvascular disease is defined by an index of microvascular resistance (IMR) \>23 or myocardial perfusion heterogeneity imaging (MPHI) \> 4 using SPECT or CMR.
Major adverse cardiovascular events (MACE) will be assessed 1 year, 2 years and 5 years after enrollment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients with a cardiomyopathy
Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dilated
* Hypertrophic
* Restrictive cardiomyopathy.
Exclusion Criteria
* Breastfeeding women
* Patients under legal protection
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinique Belledonne
UNKNOWN
Groupe Hospitalier Mutualiste de Grenoble
OTHER
Centre Hospitalier Annecy Genevois
OTHER
Centre Hospitalier Metropole Savoie
OTHER
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles BARONE-ROCHETTE, PI
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Grenoble
La Tronche, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gilles BARONE-ROCHETTE, MD, PHD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02064-49
Identifier Type: OTHER
Identifier Source: secondary_id
38RC17.215
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.